Affordable Access

deepdyve-link
Publisher Website

Circulating biomarkers in the early detection of hypertensive heart disease: usefulness in the developing world.

Authors
  • Ojji, Dike1
  • Libhaber, Elena2
  • Lamont, Kim2
  • Thienemann, Friedrich3, 4, 5
  • Sliwa, Karen2, 3
  • 1 Cardiology Unit, Department of Medicine, University of Abuja Teaching Hospital, Abuja, Nigeria. , (Niger)
  • 2 Soweto Cardiovascular Research Unit, University of Witwatersrand, Johannesburg, South Africa. , (South Africa)
  • 3 Hatter Institute for Cardiovascular Research in Africa, Department of Medicine and Cardiology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. , (South Africa)
  • 4 Department of Internal Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland. , (Switzerland)
  • 5 Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. , (South Africa)
Type
Published Article
Journal
Cardiovascular diagnosis and therapy
Publication Date
Apr 01, 2020
Volume
10
Issue
2
Pages
296–304
Identifiers
DOI: 10.21037/cdt.2019.09.10
PMID: 32420112
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Although the varying phenotypic spectra of hypertensive heart disease (HHD) can be assessed by electrocardiography (ECG), echocardiography and cardiovascular magnetic resonance (CMR), ECG criteria for left ventricular hypertrophy (LVH) are insensitive, while echocardiography and CMR are expensive, less readily available and often lack requisite expertise. Consequently, the use of circulating biomarkers in the diagnosis and prognostication of HHD beyond the traditional N-terminal pro- b-type natriuretic peptide (NT-proBNP) and B-type natriuretic peptide (BNP) have become an attractive alternative. We carried out a PubMed and Google Scholar databases' search of original articles on circulating biomarkers used in the diagnosis of the different spectrum of HHD over the last 10 years [2005-2015] in humans. Fourteen studies met the inclusion criteria with NT-pro BNP being the most studied circulating biomarker in HHD followed by soluble ST2 (sST2). There is a lack of data on the use of circulating biomarkers in HHD. There is a need to explore further this area of investigative cardiology. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.

Report this publication

Statistics

Seen <100 times